Life Sciences Archive » April, 2009

Life Sciences - April, 2009

153 articles

• Warner Chilcott Targets 2 Over Prenatal Drug Patent
• How Healthy Is The Federal Preemption Defense?
• FDA Slaps Botox, Similar Toxins With MedWatch Alert
• Zyprexa MDL Class Wants Court To Name Doctors
• Suit By Patients, Zurich Over Actimmune Tossed
• License To Lawsuit: The Path Grows Shorter
• Roche Wins Safe Harbor For Mircera Tests — For Now
• Roche Unit Recalls Defective Insulin Pumps
• Facing Enforcement Of The False Statements Act
• Medtronic Alloy Patent Suit Withstands AGA Assault
• Novartis Loses Bid For Jury Trial In Famvir Patent Suit
• 3rd Circ. Remands Preemption Cases V. GSK, Pfizer
• Tadalafil In Erectile Dysfunction Pills Sparks Recall
• FDA Says OTC Pain Pill Labels Must Be Revised
• McNeil Not At Fault In Infant Tylenol Death: Court
• Dozens Of States Probe Abilify Marketing
• Enzon Sues Shareholder For Trying To Oust CEO
• Providers Hit Merck With Suit Over Vioxx
• FDA OKs Emergency Drug Uses As Swine Flu Spreads
• Bill Seeks More FDA Scrutiny Of Foreign Medical Cos.
• $45M Settlement Reached In Becton Hypodermic MDL
• Infant Formula Maker Squirts Rival With Another Suit
• Financial Crisis And Merger Review Standards
• GSK May Exit Treximet Spat But Remain On Hook
• Judge In KV Securities Case To Oversee ERISA Suits
• GSK, Firm Make Deal Over Subpoena In Flonase Fight
• Watson Pharmaceuticals Sued Over Mucinex ANDAs
• Pozen Sues Teva Over Migraine Drug ANDA
• High Court Rejects Sanofi Inequitable Conduct Appeal
• Northgate Infringes Lexion Laparoscopy Patent: Judge
• Conn.'s Non-Medicaid Claims Cut From Zyprexa MDL
• Kimberly-Clark Sues Tyco Over Trachea Tube Patent
• Pronova Targets Teva Over Lovaza ANDA
• $250M Settles TriCor Antitrust Class Suit V. Abbott
• 'Lubricious' Glass Sex Toy Patent Obvious: Fed Circ.
• Galderma Drops MetroGel Patent Suit V. Tolmar
• Genzyme Sues Eagle Pharma Over Hectorol ANDA
• Merck-Medco Dropped From Vioxx ERISA Litigation
• CIBA, Rembrandt Settle Contact Lens Patent Suit
• High Court Asked To Hear Reverse Payments Case
• DOJ Targets Immucor In Reagents Antitrust Probe
• House Panel Balks At Changes To Patent Bill
• Teva Hit With Injunction In Evista Patent Suit V. Lilly
• DOJ Monopoly Crackdown May Hit Hurdles In Courts
• Sidley Austin Scores Ex-Congress Public Health Atty
• Being Patent Counsel Today Is Tougher Than Ever
• Sepracor Sues Mylan Over Generic Lunesta Plans
• Pfizer, J&J Shareholders Vote On Say On Pay
• UC Regents DNA Patent Case V. Dako To Proceed
• Brazilians Target Eli Lilly, Others Over Toxic Waste
• Hansen Medical Wins $36M In Trade Secrets Case
• Sanofi Whistleblower Suit Survives Bid To Dismiss
• Covidien Hits Bard With Surgical-Mesh Patent Suit
• Effects Of Physician Regulatory Actions On Insurance
• Rx.com's Group Boycott Suit Time-Barred: 5th Circ.
• Universal ABC Recalls Diet Pills Over Sibutramine
• Par, Reliant Settle ANDA Suit Over Generic Rythmol
• P&G, Roche Drop Actonel Patent Suit Against Sun
• Retroactivity In The Medical Device Safety Act
• U Of Neb. Sues Siemens Unit Over Lab Testing Patent
• Teva, Glenmark Resolve Spat Over Coreg Patents
• Guidant Fights 3rd-Party Payors' Class Action Appeal
• High Court Snubs Gilead's Loss Causation Appeal
• Alston & Bird Nabs Greenberg IP Partner
• Biomet Targeted In DOJ's Bone Growth Device Probe
• Supreme Court Rejects Jailed Fen-Phen Atty's Appeal
• Trasylol Plaintiffs Fight Bayer For 'Privileged' Docs
• Schering To Appeal Outside Sales Issue In OT Suit
• Eisai Bid To Affirm Validity Refused In Aricept Suit
• Nonparty Discovery In Reinsurance Arbitrations
• Sepracor Claims Patent Priority Over Wyeth's Pristiq
• 3rd Merck Singulair Suit Stayed For Ruling In 1st Case
• Pfizer Merger Hangs Wyeth Investors Out To Dry: Suit
• DOJ Subpoenas Smith & Nephew Over Exogen
• Texas Court Revives Prempro Case V. Wyeth
• KV Faces Class Action Over Recalled Generic Toprol
• Apotex Can't Launch Generic Pulmicort Yet: Judge
• Par Files Declaratory Suit Over Diabetes Generic
• Citigroup Sold ARS After Market Collapsed: Suit
• Impax Securities Plaintiffs Seek To Finalize $9M Deal
• Medicis, Perrigo Settle Fight Over Dermatitis Drug
• Bayer Agrees To Settle Some Contrast Dye Suits
• Liquidating AtheroGenics Sells Off All Its Assets
• 2 Firms Tapped To Lead Securities Case V. KV
• Spoliation Hearing Granted In Lexapro Patent Suit
• SEC, Ex-McKesson Exec Settle Insider Trading Case
• A New Code Of Conduct For Health Care Industry
• FLSA Suit By Shuttle Drivers Gets Judge's Nod
• Pfizer Detrol Patent Still Enforceable: Judge
• 3rd Circ. Backs Lilly In ERISA Reversal
• FDA Takes Step Toward Allowing ANDAs For Zometa
• Teleflex Balloon Pump Catheters In Class I Recall
• FTC Draws Senior Staff From Boies, Sonnenschein
• Daiichi Sues 11 Generics Cos. Over Levaquin Patents
• DOJ Shift On Pay-For-Delay Puts Focus On Courts
• Roche Sues Mylan Over Generic Xeloda ANDA
• Biotech Takes Smaller Share Of Securities Suits In '08
• Move For Interlocutory Appeal Denied In Reglan Case
• Royalty Rate Set In Boston, Cordis Stent Spat
• Drug Sellers Move To Finalize $250M TriCor Settlement
• Coughlin Stoia, Others Seek $4.5M Of Drug Suit Deal
• Wyeth Targets Zydus In New Effexor XR Patent Suit
• FDA Enjoins Pharmas From Selling Unapproved Drugs
• SOX Ruling Nixes Bias Suit V. Bristol-Myers: 3rd Circ.
• Pharma Mergers Could Stifle Drug Innovation: AAI
• French Antitrust Fines For Defibrillator Cos. Upheld
• Ariad Patent Claims In Suit V. Eli Lilly Invalid: Court
• FTC Loses Venue Fight In Reverse Payment Deal Suit
• FDA To Review Classification Of 25 Class III Devices
• Deaths Prompt Genentech To Pull Psoriasis Drug
• Keeping The FDA Honest: Interpreting Label Claims
• Schering, Mylan Settle Generic Clarinex Patent Case
• Judge Mulls Vioxx Attys' Challenge To Fee Cap
• Bayer Gets Two More Baycol Plaintiffs Tossed
• Drugmakers' Google Links Draw Wrath Of FDA
• Lilly, Plaintiff Group Settle Zyprexa MDL Claims
• Watson Loses Bid To Toss Suit Over Fentora ANDA
• AstraZeneca Tries To Halt Apotex Pulmicort Launch
• Jury Orders Fen-Phen Attorneys To Disgorge $30M
• Epix To File For Bankruptcy If Restructuring Flops
• Allergan Sues Sandoz Over Glaucoma Drug ANDA
• Next Battleground In EU Antitrust Litigation
• Securities Class Action V. Threshold Pared Down
• Biologics Legislation In The 111th Congress
• Biovail Fires Back At AstraZeneca In Seroquel IP Suit
• Closer Scrutiny Of 'Confidential Informants'
• Drug Co. Manager Pleads Guilty To Bextra Charges
• US, NJ Seek Court OK For $100M Superfund Deal
• Judge Stays Sanofi Safety Needle Patent Suit
• Genzyme Sues Impax Labs Over ANDA For Renvela
• Correction: BMS Exec Pleads Guilty Over Plavix Deal
• Jury Convicts Fen-Phen Lawyers In Fraud Case
• FDA Eyes Heart Risks Of Proposed Lundbeck Drug
• Boehringer Moves To Delay Sales Rep FLSA Trial
• Sperm Bank Subject To Strict Liability Claim: Judge
• Fed Circ. Rejects Amgen Bid For DNA Patent
• Pfizer Buries Hatchet With Nigerian State
• Neurontin Class Action V. Pfizer Dismissed
• Pfizer Gets 2nd Request For Info On $68B Wyeth Deal
• Medtronic Judge Won't Reconsider Recusing Himself
• Bill Would Make Competition For Pharma Sales Reps
• Medtronic, Acacia Unit Settle Over Catheter Patent
• Investor Sues For Axcelis Docs On Rejected Merger
• Senate Panel Pushes Through Patent Bill
• Shire Sues Natco Pharma Over ANDA For Fosrenol
• Allstate Loses Bid To Toss Wyeth Coverage Spat
• Sandoz, Ratiopharm Infringe Oxycontin Patents: Court
• Both Parties' Motions Shot Down In Ethyol Patent Suit
• Securities Suit V. America Service Group Stays Alive
• Sun's Cardene ANDA Infringes EKR Patent: Judge
• Qiagen's HPV Test Patent Not Infringed: Fed. Circ.
• Ballard Scores IP, Biotech Lawyer From MoFo
• Secret Source Dooms Merger Suit V. Bioenvision